Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TKPHF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
TAKEDA PHARMACEUTICAL CO LTD director and President, R&D Andrew Stewart Plump reported a sale of 165,393 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, he holds 766,569 ADSs directly and 281,307 ADSs indirectly through a trust.
Takeda Pharmaceutical Co Ltd executive Marcello Pignagnoli, Head of Strategic & Portfolio Development, reported a sale of 22,957 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. According to the disclosure, this was a mandatory sale to cover taxes associated with the vesting of equity awards. Following the transaction, Pignagnoli directly held 176,977 ADS.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of OBU, reported selling 50,012 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. A footnote states this was a mandatory sale to cover taxes on vesting equity awards. She now directly holds 252,010 ADS.
Takeda Pharmaceutical Co Ltd reports that executive Shannon Elaine Mary, President, Global Supply & Quality, sold 3,978 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The company notes this was a mandatory sale to cover taxes associated with vesting equity awards. After the transaction, Mary held 63,333 ADSs directly.
Takeda Pharmaceutical Co Ltd executive Gabriele Ricci, Chief Data & Tech. Officer, reported a sale of 25,088 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards, and Ricci now directly holds 171,654 ADSs.
Takeda Pharmaceutical (TAK) executive Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling 6,774 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. After this sale, she directly holds 53,029 ADS.
Takeda Pharmaceutical Co Ltd President and CEO Julie So-Young Kim reported selling 89,090 American Depositary Shares on August 10, 2026 at a weighted average price of $17.10 per share. The company states this was a mandatory sale to cover taxes on vesting equity awards, leaving her with 391,489 ADS held directly.
TAKEDA PHARMACEUTICAL CO LTD executive Giles Richard Platford, President, IBU, reported a sale of 31,083 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. According to the disclosure, this was a mandatory sale to cover taxes tied to the vesting of equity awards, and his direct holdings after the transaction were 315,838 ADSs. The transaction was reported as a sale in the open market or a private transaction and was not marked as executed under a Rule 10b5-1 trading plan.
Takeda Pharmaceutical Co. Ltd. reported that its Global General Counsel, Natalie Anne Marie Furney, executed a sale of 30,868 American Depositary Shares on August 10, 2026. The sale, at a weighted average price of $17.10 per ADS, was a mandatory sale to cover taxes associated with the vesting of equity awards. Following this transaction, Furney directly holds 204,298 ADSs of Takeda.
Takeda Pharmaceutical Co. Ltd. reported that Shannon Elaine Mary, Pres., Global Supply & Quality, sold 20,363 American Depositary Shares on 2026-08-11 in a sale categorized as an open market or private transaction at $17.55 per ADS. Following this sale, she directly holds 67,311 ADS.